A review of brain imaging biomarker genomics in Alzheimer’s disease: implementation and perspectives

10Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disease with phenotypic changes closely associated with both genetic variants and imaging pathology. Brain imaging biomarker genomics has been developed in recent years to reveal potential AD pathological mechanisms and provide early diagnoses. This technique integrates multimodal imaging phenotypes with genetic data in a noninvasive and high-throughput manner. In this review, we summarize the basic analytical framework of brain imaging biomarker genomics and elucidate two main implementation scenarios of this technique in AD studies: (1) exploring novel biomarkers and seeking mutual interpretability and (2) providing a diagnosis and prognosis for AD with combined use of machine learning methods and brain imaging biomarker genomics. Importantly, we highlight the necessity of brain imaging biomarker genomics, discuss the strengths and limitations of current methods, and propose directions for development of this research field.

Cite

CITATION STYLE

APA

Li, L., Yu, X., Sheng, C., Jiang, X., Zhang, Q., Han, Y., & Jiang, J. (2022, December 1). A review of brain imaging biomarker genomics in Alzheimer’s disease: implementation and perspectives. Translational Neurodegeneration. BioMed Central Ltd. https://doi.org/10.1186/s40035-022-00315-z

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free